Cargando…
A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain
Objective: An examination of whether oxycodone/naloxone prolonged-release tablets (OXN PR) can improve constipation and maintain analgesia, compared with oxycodone prolonged-release tablets (OxyPR) in patients with moderate/severe cancer pain. Methods: Randomized, double-blind, active-controlled, do...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255516/ https://www.ncbi.nlm.nih.gov/pubmed/21937568 http://dx.doi.org/10.1177/0269216311418869 |
_version_ | 1782221014313205760 |
---|---|
author | Ahmedzai, Sam H Nauck, Friedemann Bar-Sela, Gil Bosse, Björn Leyendecker, Petra Hopp, Michael |
author_facet | Ahmedzai, Sam H Nauck, Friedemann Bar-Sela, Gil Bosse, Björn Leyendecker, Petra Hopp, Michael |
author_sort | Ahmedzai, Sam H |
collection | PubMed |
description | Objective: An examination of whether oxycodone/naloxone prolonged-release tablets (OXN PR) can improve constipation and maintain analgesia, compared with oxycodone prolonged-release tablets (OxyPR) in patients with moderate/severe cancer pain. Methods: Randomized, double-blind, active-controlled, double-dummy, parallel-group study in which 185 patients were randomized to receive up to 120 mg/day of OXN PR or OxyPR over 4 weeks. Efficacy assessments included Bowel Function Index (BFI), Brief Pain Inventory Short-Form (BPI-SF), laxative and rescue medication use. Quality of life (QoL) and safety assessments were conducted. Results: After 4 weeks, mean BFI score was significantly lower with OXN PR; mean total laxative intake was 20% lower with OXN PR. Mean BPI-SF scores were similar for both treatments and the average rate of analgesic rescue medication use was low and comparable. QoL assessments were stable and comparable with greater improvements in constipation-specific QoL assessments with OXN PR. Overall, rates of adverse drug reactions were similar. Conclusions: OXN PR provides superior bowel function in cancer pain patients, compared with OxyPR, without compromising analgesic efficacy or safety. This study confirms that OXN PR is well tolerated and efficacious in cancer pain patients and results are in line with those seen in non-malignant pain patients. |
format | Online Article Text |
id | pubmed-3255516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-32555162012-01-23 A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain Ahmedzai, Sam H Nauck, Friedemann Bar-Sela, Gil Bosse, Björn Leyendecker, Petra Hopp, Michael Palliat Med Original Articles Objective: An examination of whether oxycodone/naloxone prolonged-release tablets (OXN PR) can improve constipation and maintain analgesia, compared with oxycodone prolonged-release tablets (OxyPR) in patients with moderate/severe cancer pain. Methods: Randomized, double-blind, active-controlled, double-dummy, parallel-group study in which 185 patients were randomized to receive up to 120 mg/day of OXN PR or OxyPR over 4 weeks. Efficacy assessments included Bowel Function Index (BFI), Brief Pain Inventory Short-Form (BPI-SF), laxative and rescue medication use. Quality of life (QoL) and safety assessments were conducted. Results: After 4 weeks, mean BFI score was significantly lower with OXN PR; mean total laxative intake was 20% lower with OXN PR. Mean BPI-SF scores were similar for both treatments and the average rate of analgesic rescue medication use was low and comparable. QoL assessments were stable and comparable with greater improvements in constipation-specific QoL assessments with OXN PR. Overall, rates of adverse drug reactions were similar. Conclusions: OXN PR provides superior bowel function in cancer pain patients, compared with OxyPR, without compromising analgesic efficacy or safety. This study confirms that OXN PR is well tolerated and efficacious in cancer pain patients and results are in line with those seen in non-malignant pain patients. SAGE Publications 2012-01 /pmc/articles/PMC3255516/ /pubmed/21937568 http://dx.doi.org/10.1177/0269216311418869 Text en © The Author(s) 2011 http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Ahmedzai, Sam H Nauck, Friedemann Bar-Sela, Gil Bosse, Björn Leyendecker, Petra Hopp, Michael A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain |
title | A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain |
title_full | A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain |
title_fullStr | A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain |
title_full_unstemmed | A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain |
title_short | A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain |
title_sort | randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255516/ https://www.ncbi.nlm.nih.gov/pubmed/21937568 http://dx.doi.org/10.1177/0269216311418869 |
work_keys_str_mv | AT ahmedzaisamh arandomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT nauckfriedemann arandomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT barselagil arandomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT bossebjorn arandomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT leyendeckerpetra arandomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT hoppmichael arandomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT ahmedzaisamh randomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT nauckfriedemann randomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT barselagil randomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT bossebjorn randomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT leyendeckerpetra randomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain AT hoppmichael randomizeddoubleblindactivecontrolleddoubledummyparallelgroupstudytodeterminethesafetyandefficacyofoxycodonenaloxoneprolongedreleasetabletsinpatientswithmoderateseverechroniccancerpain |